Future perspectives of chemotherapy for advanced gastric cancer

Gastric Cancer

Volumn 12, Issue SUPPL. 1, 2009, Pages 60-66

  Ohtsu, Atsushi ^a   Fuse, Nozomu ^a   Yoshino, Takayuki ^a   Tahara, Makoto ^a   Doi, Toshihiko ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Chemotherapy; Gastric cancer; Molecular targeting agent

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LAPATINIB; MATUZUMAB; MK 2461; OXALIPLATIN; PACLITAXEL; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADVANCED CANCER; ANGIOGENESIS; APOPTOSIS; ARTERY THROMBOSIS; BREAST CANCER; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG MECHANISM; ESOPHAGUS CANCER; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; JAPAN; KOREA; LUNG NON SMALL CELL CANCER; METASTASIS; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; STOMACH PERFORATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; VEIN THROMBOSIS;

EID: 64949108769     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-008-0461-z     Document Type: Review

References (30)

1. N. Boku S. Yamamoto K. Shirao T. Doi A. Sawaki W. Koizumi 2007 Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912) (abstract) J Clin Oncol 25 LBA4513
2. H. Narahara W. Koizumi T. Hara T. Takagane M. Akiya K. Takagi 2007 Randomized phase III study of S-1 alone versus S-1 + cisplatin in the treatment for advanced gastric cancer (the SPIRITS trial). SPIRITS: S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer J Clin Oncol 25 4514
3. A. Ohtsu Y. Shimada K. Shirao N. Boku I. Hyodo H. Saito 2003 Randomized phase III trial of 5-fluorouracil alone versus 5-fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin C in patients with unresectable advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG 9205) J Clin Oncol 21 54 59
4. M. Dank J. Zaluski C. Barone V. Valvere C. Peschel M. Wenczl 2005 Randomized phase 3 trials of irinotecan (CPT-11) + 5 FU/folinic acid (FA) vs CDDP+ 5 FU in first-line advanced gastric cancer patients (abstract) J Clin Oncol 23 4003
5. E. Van Cutsem V.M. Moiseyenko S.A. Tjulandin A. Majiris M. Constenla C. Boni 2006 Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as firstline therapy for advanced gastric cancer: a report of the V325 study group J Clin Oncol 24 4991 4997
6. D. Cunningham S. Rao N. Starling T. Ivelson M. Nicolson F. Coxon 2006 Randomized multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: the REAL 2 trial (abstract) J Clin Oncol 24 4092
7. Y. Kang W.K. Kang D.B. Shin J. Chen J. Xiong J. Wang 2006 Randomized phase III trial of capecitabine/cisplatin (XP) vs continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients with advanced gastric cancer (AGC) (abstract) J Clin Oncol 24 LBA4018
8. J.A. Ajani J. Faust K. Ikeda J.C. Yao H. Anbe K.K.L. Carr 2005 Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma J Clin Oncol 23 6957 6965
9. J.A. Ajani F.C. Lee D.A. Singh D.G. Haller H.J. Lenz A.B. Benson 2006 Multi-center phase II study of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma J Clin Oncol 24 663 667
10. J. Mendelsohn 2000 Targeting the epidermal growth factor receptor for cancer therapy J Clin Oncol 20 1S 13S
11. Y. Kitagawa M. Ueda N. Ando S. Ozawa N. Shimizu M. Kitajima 1996 Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma Clin Cancer Res 2 909 914
12. I. Garcia F. Vizoso A. Martin L. Sanz O. Adbel-Lah P. Raigoso 2003 Clinical significance of epidermal growth factor receptor and HER2 receptor in resectable gastric cancer Ann Surg Oncol 10 234 241
13. T. Doi W. Koizumi S. Siena S. Cascinu A. Ohtsu M. Michael 2003 Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer (abstract) Proc Am Soc Clin Oncol 22 1036
14. T. Dragovich S. McCoy C. Fenoglio-Preiser J. Wang J.K. Benedetti A.F. Baker 2006 SWOG 0127 phase II trial of erlotinib in GEJ and gastric adenocarcinoma J Clin Oncol 24 4922 4927
15. T. Doi A. Ohtsu N. Saijo H. Takiuchi Y. Ohhashi D. Weber 2005 A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD72000 (matuzumab) administered weekly in Japanese patients with advanced solid tumors; safety, PK and PD results of skin biopsies (abstract) J Clin Oncol 23 3077
16. C. Pinto F. Di Fabio S. Siena S. Cascinu F.L. Rojas Llimpe C. Ceccarelli 2007 Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) Ann Oncol 18 510 517
17. S. Rao N. Starling M. Benson A. Massey A. Wotherspoon G. Brown 2005 Phase I study of the humanized epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with ECX (epirubicin, cisplatin and capecitabine) as first line treatment for advanced oesophagogastric (OG) adenocarcinoma (abstract) J Clin Oncol 23 4028
18. T. Yano T. Doi A. Ohtsu N. Boku K. Hashizume M. Nakanishi 2006 Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer Oncol Rep 15 65 71
19. C.E. Geyer J. Forster D. Lindquist S. Chan C.G. Romieu T. Pienkowsky 2006 Lapatinib plus capecitabine for HER-2 positive advanced breast cancer N Engl J Med 355 2733 2743
20. S. Iqbal B. Goldman H.J. Lenz C.M. Fenoglio-Preiser C.D. Blanke 2007 S0413: a phase II study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer (abstract) J Clin Oncol 25 4621
21. N. Ferrara H.P. Gerber J. LeCouter 2003 The biology of VEGF and its receptors Nat Med 9 669 676
22. M.A. Shah R.K. Ramanathan D.H. Ilson A. Levnor D. D'Adamo E. O'Reilly 2006 Multicenter phase II study of irinotecan, cisplatin and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma J Clin Oncol 24 5201 5206
23. Enzinger PC, Fidias P, Meyerhardt J, Stuart C, Fuchs M, Huberman M, et al. Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. Gastrointestinal Cancers Symposium, San Franciso, USA, 2006 (abstract 68).
24. Y.J. Bang Y. Kang W. Kang N. Boku H. Chung S. Lanzalone 2007 Sunitinib as second line treatment for advanced gastric cancer: preliminary results from a phase II study (abstract) J Clin Oncol 25 4603
25. J. Holash S. Davis N. Papadopoulos S.D. Croll L. Ho M. Russell 2002 VEGF-trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci U S A 99 11 393 11 398
26. F. Rojo J. Tabernero J. Albanell E. Van Cutsem A. Ohtsu T. Doi 2006 Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma J Clin Oncol 24 4309 4316
27. A. Awada F. Cardoso C. Fontaine L. Dirix J. De Greve C. Sotiriou 2008 The oral mTOR ihnhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics Eur J Cancer 44 84 91
28. M. Nakajima H. Sawada Y. Yamada A. Watanabe M. Tatsumi J. Yamashita 1999 The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas Cancer 85 1894 1902
29. N. Sasaki T. Morisaki K. Hashizume T. Yao M. Tsuneyoshi H. Noshiro 2001 Nuclear factor kappa B p65 (Rel A) transcription factor is constitutively activated in human gastric carcinoma tissue Clin Cancer Res 7 4136 4142
30. Ocean AJ, Schnoll-Sussman F, Keresztes R, Chen X, Holloway S, Matthews N, et al. Phase II study of PS-341 (bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA) (abstract). J Clin Oncol 2006;24:14040.